NewsNovo
Federal Trade Commission and seven states have asked a federal court to hold Martin Shkreli in contempt for what they describe as flagrant and repeated violations of a court order banning him from working in the pharmaceutical industry.
This legal move marks a significant escalation in the dispute over Shkreli's post-release activities, raising questions about the enforceability of industry bans for convicted fraudsters.
Shkreli, widely known as "pharma bro," gained notoriety for defending his decision to raise the price of a drug by 5,000%. He was sentenced to seven years in prison in 2018 for defrauding investors.
Prior to his release in 2022, a court permanently banned him from the industry, citing his illegal attempts to prevent generic competition for a specific drug.
Keep reading